Camobucol is an orally active, anti-inflammatory compound. It also is a phenolic antioxidant with antirheumatic properties.

Camobucol demonstrates strong antioxidant properties, effectively combating lipid peroxides in vitro and showing improved absorption by cells. It also selectively suppresses levels of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1 induced by tumor necrosis factor (TNF)-α, while minimally affecting E-selectin and not altering intracellular adhesion molecule-1 expression in endothelial cells. Moreover, Camobucol does not interfere with the TNF-α-driven relocation of NF-κB into the nucleus. It further reduces cytokine-stimulated production of monocyte chemoattractant protein-1, interleukin (IL)-6, and IL-8 in endothelial cells and human fibroblast-like synoviocytes, and curtails the release of TNF-α, IL-1β, and IL-6 after lipopolysaccharide exposure in human peripheral blood mononuclear cells.